Gene therapy for hearing loss caused by TOMT mutations
Cell type-specific gene therapy approach for TOMT-linked congenital hearing loss
This study is working on a new gene therapy to help people with congenital hearing loss caused by TOMT mutations, aiming to create a treatment that directly targets the right cells in the ear to improve hearing with fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Echogenesis Therapeutics INC NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11066259 on NIH RePORTER |
What this research studies
This research focuses on developing a targeted gene therapy for congenital hearing loss linked to TOMT mutations. By utilizing a precision medicine approach, the team aims to create therapies that specifically target the affected cell types in the cochlea, minimizing side effects and maximizing therapeutic benefits. The methodology involves computational screening and in vivo testing to identify specific genomic promoter fragments that can effectively express therapeutic genes in cochlear hair cells. This innovative approach seeks to address the limitations of current gene therapies that do not adequately restore hearing.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with congenital hearing loss due to TOMT mutations.
Not a fit: Patients with hearing loss not linked to TOMT mutations or those with other unrelated forms of hearing impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective gene therapies that restore hearing in patients with TOMT-linked congenital hearing loss.
How similar studies have performed: Previous research using adeno-associated viral gene therapies for other forms of genetic hearing loss has shown promise, indicating potential for success with this novel approach.
Where this research is happening
Pittsburgh, United States
- Echogenesis Therapeutics INC — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Cunningham, Christopher L — Echogenesis Therapeutics INC
- Study coordinator: Cunningham, Christopher L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.